全球肺癌治疗市场 – 行业趋势及 2029 年预测

全球肺癌治疗市场分析及规模

癌症是指因细胞异常生长而引起的基因疾病。这些异常细胞通过血液和淋巴系统从原发部位进一步迁移到其他部位。肺癌是一种在肺部组织中形成的癌症。人们对癌症认识的提高正在推动肺癌治疗市场的增长。

• 小细胞肺癌、肺类癌和非小细胞肺癌是三种不同类型的肺癌。2021 年全球肺癌治疗市场价值为 246.6782 亿美元，预计到 2029 年将达到 544.7511 亿美元，在 2022-2029 年预测期内复合年增长率为 10.41%。Data Bridge 市场研究团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

全球肺癌治疗市场定义

肺癌治疗是指通过药物和手术等疗法来阻止、杀死、减少或摧毁肺部的癌细胞和细胞。这种类型的癌症可通过化疗、免疫疗法、手术和放射疗法进行治疗。原发性肺癌通常源自上皮细胞。

Lung Cancer Therapeutics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:

• Prevalence of Unhealthy Lifestyles

The rise in the adoption of the unhealthy lifestyles, such as smoking acts as one of the major factors driving the growth of lung cancer therapeutics market. Cigarette smoking is known to be prominent cause of lung cancer.

• Demand for Targeted Therapies

The increase in the demand for targeted therapies, including chemotherapy, immunotherapy, surgery, and radiation therapy to treat lung cancer accelerate the market growth.

• Presence of Highly Efficient Drugs

The presence of highly efficient drugs, such as avastin, gemzar, taxotere and tarceva further influence the market.

Opportunities

Furthermore, arrival of nanomedicine to treat lung cancer extend profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, growing approvals in the lung cancer therapeutics will further expand the market.

Restraints/Challenges Global Lung Cancer Therapeutics Market

On the other hand, presence of poor cancer diagnostic facilities in many countries and the adverse effects of chemotherapies are expected to obstruct market growth. Also, stringent regulations are projected to challenge the lung cancer therapeutics market in the forecast period of 2022-2029.

This lung cancer therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on lung cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Lung Cancer Therapeutics Market

The medical services such as lung cancer therapeutics witnessed decline in revenues in the years 2020 and 2021 due to the outbreak of COVID-19. Major medical procedures were declined during the pandemic in order to prevent the risk of spreading coronavirus. However, rise in the lung cancer therapeutics procedures is expected in the post-COVID owing to the easing of restrictions.

Recent Development

• AdoRx Therapeutics, announced regarding their strategic collaboration with Lung Cancer Initiative at Johnson & Johnson and Johnson & Johnson Innovation LLC in February’2019. AdoRx has granted an exclusive option to research, develop and commercialise novel antagonists under the terms of the agreement.

Global Lung Cancer Therapeutics Market Scope and Market Size

The biomarkers market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cancer Type

• Non-Small Cell Lung Cancer
• Metastatic Lung Cancer
• Mesothelioma
• Chest Wall Tumours
• Pulmonary Neuroendocrine Tumours
• Mediastinal Tumours

On the basis of cancer type, the lung cancer therapeutics market is segmented into non-small cell lung cancer, metastatic lung cancer, mesothelioma, chest wall tumours, pulmonary neuroendocrine tumours and mediastinal tumours.

Molecule Type

• Small Molecules
• Biologics

On the basis of molecule type, the lung cancer therapeutics market is segmented into small molecules and biologics.

Drug Class

• Alkylating Agents
• Antimetabolites
• Mitotic Inhibitors
• Multikinase Inhibitors
• EGFR Inhibitors
• Others

On the drug class, the lung cancer therapeutics market is segmented into alkylating agents, antimetabolites, mitotic inhibitors, multikinase inhibitors, EGFR inhibitors and others.

Treatment Type

• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Other Drugs

On the basis of treatment type, the lung cancer therapeutics market is segmented into radiation therapy, chemotherapy, targeted therapy, immunotherapy, and other drugs.

Therapy Type

• Single Drug Therapy
• Combination Therapy

On the basis of therapy type, the lung cancer therapeutics market is segmented into single drug therapy and combination therapy.

End User

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end user, the lung cancer therapeutics market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online
• Others

On the basis of distribution channel, the lung cancer therapeutics market is segmented into hospital pharmacy, retail pharmacy, online and others.

Lung Cancer Therapeutics Market Regional Analysis/Insights

The lung cancer therapeutics market is analysed and market size insights and trends are provided by country, cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel as referenced above.

The countries covered in the lung cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the lung cancer therapeutics market because of the rise in incidence of lung cancer and growing aging population within the region.

Asia-Pacific (APAC) is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increased use of lung cancer therapeutic due to rising tobacco smoking in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The lung cancer therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lung cancer therapeutics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lung cancer therapeutics market. The data is available for historic period 2010-2020.

Competitive Landscape and Lung Cancer Therapeutics Market Share Analysis

The lung cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lung cancer therapeutics market.

Some of the major players operating in the lung cancer therapeutics market are Church & Dwight Co., Inc. (US), GlaxoSmithKline plc. (UK), Pfizer Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), ONO PHARMACEUTICAL CO., LTD. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Lily. (US), AstraZeneca (US), Boehringer Ingelheim International GmbH (Germany), Merck & Co., Inc. (US), CELGENE CORPORATION (US), Sanofi (France), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), ALLERGAN (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), and Bristol-Myers Squibb Company (US), among others.

Research Methodology : Global Lung Cancer Therapeutics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/zh/speak-to-analyst/?dbmr=global-lung-cancer-therapeutics-market

SKU-23996